Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA.

J Clin Oncol. 2010 Apr 1;28(10):1652-9. doi: 10.1200/JCO.2009.22.8585. Epub 2010 Mar 1.

PMID:
20194865
[PubMed - indexed for MEDLINE]
Free Article
2.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.

J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23.

PMID:
19933912
[PubMed - indexed for MEDLINE]
Free Article
3.

Detecting an overall survival benefit that is derived from progression-free survival.

Broglio KR, Berry DA.

J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9. doi: 10.1093/jnci/djp369. Epub 2009 Nov 9.

PMID:
19903805
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group.

J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.

PMID:
19704057
[PubMed - indexed for MEDLINE]
Free Article
5.

Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules.

Bushnell D.

J Natl Compr Canc Netw. 2009 Jul;7(7):760-4.

PMID:
19635228
[PubMed - indexed for MEDLINE]
6.

Neuroendocrine carcinomas of the lung: a critical analysis.

Moran CA, Suster S, Coppola D, Wick MR.

Am J Clin Pathol. 2009 Feb;131(2):206-21. doi: 10.1309/AJCP9H1OTMUCSKQW. Review.

PMID:
19141381
[PubMed - indexed for MEDLINE]
Free Article
7.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS.

Clin Cancer Res. 2009 Jan 1;15(1):338-45. doi: 10.1158/1078-0432.CCR-08-1476.

PMID:
19118063
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F.

J Clin Oncol. 2008 Sep 10;26(26):4311-8. doi: 10.1200/JCO.2008.16.7858. Erratum in: J Clin Oncol. 2008 Dec 1;26(34)5660..

PMID:
18779618
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM.

J Clin Oncol. 2008 Aug 1;26(22):3791-6. doi: 10.1200/JCO.2008.16.1711. Review. Erratum in: J Clin Oncol. 2009 Apr 20;27(12):2109-10.

PMID:
18669467
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.

King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL.

Cancer. 2008 Sep 1;113(5):921-9. doi: 10.1002/cncr.23685.

PMID:
18618495
[PubMed - indexed for MEDLINE]
Free Article
11.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.

J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020.

PMID:
18612155
[PubMed - indexed for MEDLINE]
Free Article
12.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB.

J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.

PMID:
18565894
[PubMed - indexed for MEDLINE]
Free Article
13.

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R.

Am J Clin Oncol. 2008 Jun;31(3):271-9. doi: 10.1097/COC.0b013e31815e4557.

PMID:
18525307
[PubMed - indexed for MEDLINE]
14.

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP.

J Clin Oncol. 2008 May 1;26(13):2124-30. doi: 10.1200/JCO.2007.15.2553.

PMID:
18445841
[PubMed - indexed for MEDLINE]
Free Article
15.

Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report.

Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, Cherqui D, Castaing D, Ruszniewski P, Wolf P, Paye F, Salame E, Muscari F, Pruvot FR, Baulieux J.

Am J Transplant. 2008 Jun;8(6):1205-13. doi: 10.1111/j.1600-6143.2008.02233.x. Epub 2008 Apr 29.

PMID:
18444921
[PubMed - indexed for MEDLINE]
Free Article
16.

Assessing the measure of a new drug: is survival the only thing that matters?

Sargent DJ, Hayes DF.

J Clin Oncol. 2008 Apr 20;26(12):1922-3. doi: 10.1200/JCO.2007.14.8064. No abstract available.

PMID:
18421044
[PubMed - indexed for MEDLINE]
Free Article
17.

High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.

Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA.

Genes Chromosomes Cancer. 2008 Jul;47(7):591-603. doi: 10.1002/gcc.20561.

PMID:
18383209
[PubMed - indexed for MEDLINE]
18.

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA.

J Clin Oncol. 2008 Mar 10;26(8):1316-23. doi: 10.1200/JCO.2007.13.6374.

PMID:
18323556
[PubMed - indexed for MEDLINE]
Free Article
19.

Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors.

Kim do H, Nagano Y, Choi IS, White JA, Yao JC, Rashid A.

Genes Chromosomes Cancer. 2008 Jan;47(1):84-92.

PMID:
17943967
[PubMed - indexed for MEDLINE]
20.

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B.

Virchows Arch. 2007 Oct;451(4):757-62. Epub 2007 Aug 3.

PMID:
17674042
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk